文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

前列腺癌根治性放疗联合去势治疗中的睾酮监测与补充:系统综述

Testosterone monitoring and supplementation in patients with intermediate- or high-risk prostate cancer treated with 6-36 months of androgen deprivation therapy and radiotherapy: a systematic literature review.
PubMed 文献 · Radiother Oncol · 2026-09-12

基线睾酮与肿瘤结局无关但可预测恢复;治疗中睾酮抑制至<20 ng/dL与更好结局相关;TRT不增加复发风险的证据有限。

要点

  • 治疗中睾酮抑制至<20 ng/dL可能比传统<50 ng/dL阈值与更好肿瘤结局相关。
  • ADT后睾酮恢复异质且依赖疗程,非去势水平多在6-15个月内达到,完全正常常需数年。
  • 根治后TRT不增加复发风险的证据非常有限,高危ADT联合放疗人群数据稀疏。

核心结论

  • 支持常规监测治疗中睾酮水平,并提示需前瞻性评估根治后TRT的安全性。

主要发现

  • 基线睾酮与肿瘤结局无关,但能强预测治疗后睾酮恢复。
  • 治疗中睾酮抑制至<20 ng/dL(<0.7 nmol/L)而非传统50 ng/dL(<1.7 nmol/L)阈值与更好肿瘤结局相关。
  • ADT后睾酮恢复异质且依赖ADT疗程,非去势水平多在6-15个月内达到。
  • 完全正常睾酮恢复常需数年,且相当比例患者恢复不完全。
  • 高龄、低基线睾酮和GnRH激动剂延迟恢复,口服GnRH拮抗剂则加快正常化。

关键数值与推荐

  • 治疗中睾酮抑制目标<20 ng/dL(<0.7 nmol/L)与更好肿瘤结局相关。
  • 传统去势阈值为50 ng/dL(<1.7 nmol/L)。
  • ADT后6-15个月内常达到非去势睾酮水平。

临床怎么用

  • 对接受ADT联合根治性放疗的中高危前列腺癌患者常规监测治疗中睾酮水平。
  • 关注ADT后睾酮恢复的异质性,根据疗程和患者因素预期恢复时间。

局限性

  • TRT不增加复发风险的证据来自非常有限的观察性数据。
  • 高危患者接受ADT联合放疗后TRT的证据稀疏。
  • 需前瞻性研究评估该人群中TRT的安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Androgen deprivation therapy (ADT) combined with curative-intent radiotherapy is a cornerstone for intermediate- and high-risk localised prostate cancer, yet the clinical relevance of testosterone (T) monitoring and the safety of testosterone replacement therapy (TRT) in patients with persistent symptoms of hypogonadism remain uncertain. This systematic review synthesised evidence addressing four key questions: the prognostic role of baseline T, the impact of on-treatment T levels, the kinetics and determinants of T recovery after ADT, and the oncologic safety of TRT following curative treatment. Following PRISMA 2020 guidelines, major databases and conference proceedings were searched through May 2026 using Perplexity Computer (Anthropic Sonnet 4.6 / GPT-5 family models) under the direct supervision of the principal investigators. Twenty-nine studies were included. Baseline T was not associated with oncological outcomes but was a strong predictor of T recovery after treatment. On-treatment T suppression to < 20 ng/dL (<0.7 nmol/L), rather than the conventional 50 ng/dL (<1.7 nmol/L) threshold, was associated with improved oncologic outcomes. Recovery of T after ADT was heterogeneous and dependent on ADT duration. Non-castrate levels were typically achieved within 6-15 months, but full eugonadal recovery often required years and was incomplete in a substantial proportion of patients. In addition, older age, lower baseline T, and GnRH agonist use delayed recovery, whereas oral GnRH antagonists enabled faster normalisation. Very limited observational data suggest that TRT after curative treatment does not increase recurrence risk, although evidence in high-risk patients treated with ADT and radiotherapy is sparse. These findings support routine on-treatment T monitoring and highlight the need for prospective evaluation of TRT in this setting.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Achard V, Zapatero A, Kishan AU, et al. Testosterone monitoring and supplementation in patients with intermediate- or high-risk prostate cancer treated with 6-36 months of androgen deprivation therapy and radiotherapy: a systematic literature review. Radiother Oncol. 2026. PMID: 42731757. doi:10.1016/j.radonc.2026.111777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。